OTCPK:EXNZ.F

Stock Analysis Report

Executive Summary

Exalenz Bioscience Ltd. develops and markets advanced tools for the diagnosing and managing liver and gastroenterology disorders in Israel.

Snowflake

Fundamentals

Imperfect balance sheet with weak fundamentals.

Risks

  • Exalenz Bioscience is not covered by any analysts.

Share Price & News

How has Exalenz Bioscience's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:EXNZ.F

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

n/a

OTCPK:EXNZ.F

9.9%

US Medical Equipment

1.6%

US Market

No trading data on EXNZ.F.

No trading data on EXNZ.F.


Share holder returns

EXNZ.FIndustryMarket
7 Day0%0.5%-0.02%
30 Day0%0.09%2.7%
90 Day0%2.0%1.4%
1 Yearn/a10.8%9.9%3.8%1.6%
3 Yearn/a69.0%63.9%45.2%35.8%
5 Yearn/a136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is Exalenz Bioscience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Exalenz Bioscience undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Exalenz Bioscience is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Exalenz Bioscience has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of EXNZ.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Exalenz Bioscience regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Exalenz Bioscience expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Exalenz Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of EXNZ.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Exalenz Bioscience's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Exalenz Bioscience performed over the past 5 years?

15.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Exalenz Bioscience does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Exalenz Bioscience's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Exalenz Bioscience's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Exalenz Bioscience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Exalenz Bioscience has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Exalenz Bioscience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Exalenz Bioscience's financial position?


Financial Position Analysis

Exalenz Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Exalenz Bioscience's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Exalenz Bioscience has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Exalenz Bioscience's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Exalenz Bioscience has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Exalenz Bioscience has less than a year of cash runway based on current free cash flow.

Exalenz Bioscience has less than a year of cash runway if free cash flow continues to grow at historical rates of 5% each year.


Next Steps

Dividend

What is Exalenz Bioscience's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Exalenz Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Exalenz Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Exalenz Bioscience has not reported any payouts.

Unable to verify if Exalenz Bioscience's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Exalenz Bioscience has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Exalenz Bioscience's salary, the management and board of directors tenure and is there insider trading?

4.1yrs

Average management tenure


CEO

Raffi Werner 0

3.7yrs

Tenure

US$1,326,000

Compensation

Mr. Rafael Werner, also Known as Raffi, has been the Chief Executive Officer and General Manager of Exalenz Bioscience Ltd since July 2015 and served as its Chief Operating Officer. Mr. Werner served as Ch ...


CEO Compensation Analysis

Raffi's remuneration is lower than average for companies of similar size in United States of America.

Raffi's compensation has increased whilst company is loss making.


Management Age and Tenure

4.1yrs

Average Tenure

The tenure for the Exalenz Bioscience management team is about average.


Board Age and Tenure

7.7yrs

Average Tenure

50yo

Average Age

The tenure for the Exalenz Bioscience board of directors is about average.


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Susan Alpert (71yo)

    Executive Vice President of Regulatory Affairs

    • Tenure: 0yrs
  • Ofer Schlesinger

    Vice President of Research & Development

    • Tenure: 4.5yrs
    • Compensation: US$695.00k
  • Yaron Ilan

    Medical Director

    • Tenure: 0yrs
  • Raffi Werner

    CEO & GM

    • Tenure: 3.7yrs
    • Compensation: US$1.33m
  • Gavin Doree

    Vice President of Sales & Marketing

    • Tenure: 5.7yrs
    • Compensation: US$1.19m
  • Roy Golan (45yo)

    President & CFO

    • Tenure: 0.9yrs
  • Melina Arazy

    Vice President of Clinical Affairs

    • Tenure: 0yrs
    • Compensation: US$710.00k
  • Meirav Bauer

    Investor Relations Executive

    • Tenure: 0yrs

Board Members

  • Uri Geiger (50yo)

    Chairman of the Board

    • Tenure: 12.9yrs
    • Compensation: US$315.00k
  • John Vierling (72yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Mori Arkin (65yo)

    Director

    • Tenure: 11.5yrs
  • Hani Lerman (45yo)

    Director

    • Tenure: 3.9yrs
  • Scott Friedman

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Arun Sanyal

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Mitchell Shiffman

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Michael Fried

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Julia Wendon

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Itai Arkin (30yo)

    Director

    • Tenure: 3.9yrs

Company Information

Exalenz Bioscience Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Exalenz Bioscience Ltd
  • Ticker: EXNZ.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: ₪211.344m
  • Listing Market Cap: ₪58.645m
  • Shares outstanding: 27.06m
  • Website: https://www.exalenz.com

Location

  • Exalenz Bioscience Ltd
  • 4 Ha’maayan Street
  • Modi'in-Maccabim-Re'ut
  • 7177872
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EXENTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSSep 2007
EXNZ.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDSep 2007

Biography

Exalenz Bioscience Ltd. develops and markets advanced tools for the diagnosing and managing liver and gastroenterology disorders in Israel. The company provides BreathID system, a breath-testing technology ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/03/19 00:16
End of Day Share Price2018/12/19 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.